Literature DB >> 23267122

Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Sarah Beltrami1, Richard Kim, Jennifer Gordon.   

Abstract

Neurofibromatosis type 2 protein (NF2) is an underappreciated tumor suppressor involved in a broad range of nervous system tumors. Inactivation of the NF2 gene leads to neurofibromatosis type-2, which is characterized by multiple benign nervous system tumors and mutations in the gene have been demonstrated in many other tumor types as well. All tumors, regardless of location or grade, lack a fundamental control over cell cycle progression. Historically, NF2 is an unconventional tumor suppressor protein in that it does not directly influence the cell cycle. NF2 links receptors at the plasma membrane to their cytoplasmic kinases to facilitate contact inhibition. However, NF2 can also interact with an array of cytoplasmic and nuclear proteins that affect cell cycle progression. Furthermore, through some of these pathways, NF2 may reverse the functional inhibition of conventional tumor suppressor pathways. Here we review mechanisms utilized by NF2 to regain control of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23267122      PMCID: PMC3725758     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  109 in total

1.  Interaction between JCV large T-antigen and beta-catenin.

Authors:  Dai-Di Gan; Kamel Khalili
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity.

Authors:  Chung Hun Ryu; Sae-Woong Kim; Kyu Hwa Lee; Joo Yong Lee; Hongtae Kim; Woon Kyu Lee; Byung Hyune Choi; Young Lim; Young Hoon Kim; Kweon-Haeng Lee; Tae-Kon Hwang; Tae-Youn Jun; Hyoung Kyun Rha
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

4.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 5.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

6.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

7.  Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton.

Authors:  M Laulajainen; T Muranen; O Carpén; M Grönholm
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

8.  Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

Authors:  Miguel A López-Lago; Tomoyo Okada; Miguel M Murillo; Nick Socci; Filippo G Giancotti
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

9.  Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin.

Authors:  Els Robanus-Maandag; Marco Giovannini; Martin van der Valk; Michiko Niwa-Kawakita; Vincent Abramowski; Cristina Antonescu; Gilles Thomas; Anton Berns
Journal:  Oncogene       Date:  2004-08-26       Impact factor: 9.867

10.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08
View more
  13 in total

Review 1.  Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.

Authors:  J Vaquero; T H Nguyen Ho-Bouldoires; A Clapéron; L Fouassier
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

2.  A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.

Authors:  Thinh T Nguyen; Hyun-Sung Lee; Bryan M Burt; Christopher I Amos; Chao Cheng
Journal:  Br J Cancer       Date:  2022-08-23       Impact factor: 9.075

Review 3.  Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis.

Authors:  Julien Boetto; Matthieu Peyre; Michel Kalamarides
Journal:  Acta Neurochir (Wien)       Date:  2020-11-20       Impact factor: 2.216

4.  The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.

Authors:  Cailei Zhao; Qian Chen; Chunde Li; Jian Yang; Cong Li; Yangyang Zhou; Jianxiang Liao
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

Review 5.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 6.  NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Authors:  Rebecca Dunbar Schroeder; Laura S Angelo; Razelle Kurzrock
Journal:  Oncotarget       Date:  2014-01-15

7.  Identification of candidate genes for devil facial tumour disease tumourigenesis.

Authors:  Robyn L Taylor; Yiru Zhang; Jennifer P Schöning; Janine E Deakin
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

Review 8.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

9.  An E2-ubiquitin thioester-driven approach to identify substrates modified with ubiquitin and ubiquitin-like molecules.

Authors:  Gábor Bakos; Lu Yu; Igor A Gak; Theodoros I Roumeliotis; Dimitris Liakopoulos; Jyoti S Choudhary; Jörg Mansfeld
Journal:  Nat Commun       Date:  2018-11-14       Impact factor: 14.919

10.  Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females.

Authors:  Agus Supartoto; Muhammad Bayu Sasongko; Datu Respatika; Indra Tri Mahayana; Suhardjo Pawiroranu; Hari Kusnanto; Dhimas Hari Sakti; Prima Sugesty Nurlaila; Didik Setyo Heriyanto; Sofia Mubarika Haryana
Journal:  Front Oncol       Date:  2019-01-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.